+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group



Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group



Cancer Treatment Reports 71(12): 1203-1207



Thirty-two patients with advanced Hodgkin's lymphoma resistant to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) were treated with a salvage chemotherapy regimen consisting of lomustine, etoposide, vindesine, and dexamethasone (CEVD). Twenty-seven patients were treated because of primary resistance to COPP/ABVD, and five patients were treated in early relapse (less than 12 months) after COPP/ABVD-induced complete remission. Fourteen patients (44%) achieved complete remission, and four patients achieved partial remission, with an overall response rate of 56%. Two partial responders achieved complete remission after additional radiotherapy. Four of five patients in early relapse after COPP/ABVD achieved complete remission. Consolidation radiotherapy was given for only one complete responder. Median duration of complete remission is greater than 10 months, and median survival is greater than 26 months. The treatment was well-tolerated. The main side effects were leukopenia, thrombocytopenia, mild nausea/vomiting, and cushingoid side effects. CEVD is a very active and well-tolerated salvage chemotherapy regimen in patients with Hodgkin's disease resistant to or relapsing after COPP and ABVD.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 040594128

Download citation: RISBibTeXText

PMID: 2446751


Related references

Chemotherapy of hodgkin's lymphoma with alternating cycles of copp cyclophosphamide vincristine procarbazine prednisone and abvd doxorubicin bleomycin vinblastine and dacarbazine results of the hd1 and hd3 trials of the german hodgkin study group. Medical Oncology and Tumor Pharmacotherapy 6(2): 155-162, 1989

Chemotherapy vs radiotherapy for remission consolidation after three double cycles of cyclophosphamide vincristine procarbazine prednisone copp and doxorubicin bleomycin vinblastine dacarbazine abvd a randomized trial in patients with stages iiib iv hodgkins lymphoma. Journal of Cancer Research & Clinical Oncology 116(SUPPL PART 1): 613, 1990

Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group. Japanese Journal of Clinical Oncology 30(3): 146-152, 2000

14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology 21(9): 1734-1739, 2003

Alternating Combination Chemotherapy C-Mopp (Cyclophosphamide, Vincristine, Procarbazine, Prednisone) and Abvd (Adriamycin, Bleomycin, Vinblastine, Dacarbazine) in Clinical Stage Ii-Iv Hodgkin's Disease: a Multicenter Phase Ii Study (Jcog 8905). Japanese Journal of Clinical Oncology 30(3): 146-152, 2000

Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease. Cancer Treatment Reports 68(7-8): 947-951, 1984

Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group. Blood 92(12): 4560-4567, 1998

Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology 22(12): 2424-2429, 2004

Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone). Leukemia and Lymphoma 54(1): 36-40, 2013

Treatment of Hodgkin's disease in children with alternating mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) and adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) courses without radiotherapy. Medical and Pediatric Oncology 29(1): 23-27, 1997

Phase III trial of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) versus cisplatin, etoposide, bleomycin and prednisone (CisEBP) for the treatment of advanced non-Hodgkin's lymphoma of high grade malignancy. The Danish Lymphoma Study Group. Acta Oncologica 29(8): 995-999, 1990

Results of the treatment of hodgkin's disease in stages iii and iv with use of the doxorubicin bleomycin vinblastine dacarbazine and bleomycin doxorubicin cyclophosphamide vincristine prednisone programs. Acta Haematologica Polonica 17(3-4): 81-90, 1986

Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood 116(12): 2026-2032, 2010

Phase Iii Trial of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (Chop) Versus Cisplatin, Etoposide, Bleomycin and Prednisone (CisEbp) for the Treatment of Advanced Non-Hodgkin's Lymphoma of High Grade Malignancy. Acta Oncologica 29(8): 995-999, 1990

A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin's lymphoma. Clinical Lymphoma 1(4): 285-292, 2001